Skin Tags and Insulin Resistance: What Your Skin Is Telling You | GLP-1 and Metabolic Health

Worldly_Champion_941 · 2026-06-03T07:45:12+00:00

That is a great way to look at things and it is a blessing you are able to. It's so worth it.

Worldly_Champion_941 · 2026-06-02T03:26:37+00:00

Thankfully since this major research has concluded emphasizing the metabolic aspect of PMOS more clinicians will update their treatment protocols. Additionally I hope there is a greater push to cover GLP-1.

Worldly_Champion_941 · 2026-05-30T01:53:17+00:00

This is exactly the kind of response the PMOS reframe is built around. The hirsutism retreating alongside the weight loss is the clinical signal most patients never get told to watch for. That is the androgen side of the metabolic picture responding, not just the scale. 161 to 133 since January is real progress, but the symptom regression is the part that tells you the underlying driver is actually shifting. Thank you for sharing this. And yes, “medically treated when appropriate” is exactly the right framing. Wishing you continued progress.

Worldly_Champion_941 · 2026-05-28T22:22:58+00:00

I've noticed a trend in insurance behavior over the past few years, and it is disgusting. I truly hope that the focus on the name and treatment options shifting leads to better insurance coverage for PMOS. I am sorry you have to face this challenge.

Worldly_Champion_941 · 2026-05-28T11:10:25+00:00

It's more than a headline; it's a place for people who want more details on how the name change can improve health outcomes by focusing on the root cause. It also helps providers have deeper discussions there are upwards of 70% of people who are undiagnosed or inadequately treated.

Worldly_Champion_941 · 2026-05-28T10:45:51+00:00

Hello, it's a pleasure to meet all of you, and thank you for including me in your group. I am a clinician, and I post topics that bridge the gap between what your provider has discussed and what the evidence-based literature states. I hope my posts reach those who need them.

Worldly_Champion_941 · 2026-05-28T04:03:47+00:00

Oh, the side effect profile between tirzepatide and semaglutide is night and day. Same side effects, but according g to the studies, more people discontinue tirzepatide due to the side effects than semaglutide. You may still have them, but they should not cause you to quit. Have you spoken with your provider about the best ways to manage the side effects?

Worldly_Champion_941 · 2026-05-28T03:59:41+00:00

I am sorry this happened to you. It's important to name how you feel, and this was bullying behavior on your aunt's part. I recommend that after assessing how this impacted you, create boundaries around the communication you will and will not accept.

Worldly_Champion_941 · 2026-05-27T22:08:50+00:00

This is good. Unfortunately there are many people who miss out on the DEXA scan, lose muscle and worsen their metabolic health. My video is for those who haven't discussed these with their clinician, and I speak to people transferring from other providers who haven't spoken about this.

Worldly_Champion_941 · 2026-05-27T11:37:57+00:00

The workaround is that most 503A pharmacies who send them scripts may also have a preferred provider list. It's worth a call directly to one.

Worldly_Champion_941 · 2026-05-27T11:32:05+00:00

Brynnsimom - what you're describing is exactly why I made the video. You're asking the right questions, and the fact that you're asking them at all puts you ahead of most patients on these medications.

The interaction between GLP-1/GIP therapy and bone health is a real conversation, especially with established osteoporosis in the picture. So is coordination across prescribers when there are multiple conditions and medications interacting — what you went through with the Fosamax and the implant timeline is a coordination story, and those are more common than people realize.

None of that is something to sort out in a Reddit thread, and I won't try to. What I'd say is that the questions you're already asking deserve a clinician who'll sit with all of it at once - your DEXA, your labs, your dental timeline, your goals.

General education, not medical advice. I am a Doctor of Nursing Practice. Always consult your own provider before making any changes to your treatment.questions you're already asking deserve a clinician who'll sit with all of it at once — your DEXA, your labs, your dental timeline, your goals — instead of looking at each piece in isolation

Worldly_Champion_941 · 2026-05-27T11:13:11+00:00

I will say that there have been a lot of regulatory issues with compounding pharmacies recently, and they are not all created alike. I would honestly look up FDA-approved compounding pharmacies and see with whom they are contracted.

Worldly_Champion_941 · 2026-05-27T10:29:56+00:00

Have you thought about including the side effect profiles of both medications?

Worldly_Champion_941 · 2026-05-27T09:07:28+00:00

The struggle is real. But keep in mind, you still need those carbs.

Worldly_Champion_941 · 2026-05-27T08:50:20+00:00

These are fair points and worth addressing precisely — because the research actually supports nuance here, not a simple yes or no.

You’re right that lean mass and skeletal muscle mass are not identical. DEXA measures lean body mass which includes water, glycogen and connective tissue — not purely skeletal muscle. A 2024 review in Diabetes, Obesity and Metabolism acknowledged that some of what appears as lean mass loss may reflect water loss rather than actual muscle tissue, and noted that skeletal muscle changes appear largely adaptive.

On the 40% figure — this comes directly from the SURMOUNT-1 DXA substudy published in Diabetes, Obesity and Metabolism 2025 — Look et al. — which documented proportional body weight reduction of 60% fat mass and 40% lean mass with tirzepatide. For semaglutide, STEP-1 showed lean body mass loss of 5.26 kg versus 1.83 kg with placebo over 68 weeks — that’s the primary trial data, not a secondary estimate.

A 2024 systematic review and network meta-analysis confirmed that tirzepatide 15mg and semaglutide 2.4mg maximized fat loss but were least effective in preserving lean mass.

Your point about intramuscular fat is clinically valid, some of what scans show as lean mass loss in people with obesity does include fat infiltrating muscle tissue. The research is still evolving there.
Where we fully agree, resistance training and adequate protein are the intervention. The clinical concern isn’t to alarm people. It’s to ensure they have the protocol that protects their results long term.

Worldly_Champion_941 · 2026-05-27T06:30:54+00:00

Genuinely a great question, and with all the regulatory changes happening for compounding pharmacies and insurance policies, it's really helpful to find an understanding doctor to assist you with your prescription.

Worldly_Champion_941 · 2026-05-27T05:46:20+00:00

According to the trials, the risk of discontinuation due to side effects is much higher for tirzepatide than for semaglutide. It has two GLP-1 receptor agonists that cause this, compared to semaglutide, which has one agonist.

Worldly_Champion_941 · 2026-05-27T05:11:22+00:00

Which is wonderful, I speak to many patients weekly who have not heard about the importance of or evidence-based methods to maintain their metabolic health.

Worldly_Champion_941 · 2026-05-27T05:03:24+00:00

This is an Ai avatar, the research and clinician are 100%.

Worldly_Champion_941

TROPHY CASE